Life Sciences

  • April 29, 2026

    AbbVie Seeks Early Win Over HHS In Botox Drug Price Suit

    When the federal government included Botox in Medicare's drug price negotiation program, which allows Medicare officials to negotiate for lower drug prices, it overstepped its authority, drugmaker AbbVie Inc. told a D.C. federal court, arguing the cosmetic drug and migraine treatment is a "plasma-derived" product ineligible for price controls.

  • April 29, 2026

    Ropes & Gray Guides Italy's Chiesi On $1.9B US Biotech Deal

    Chiesi Group said Wednesday it will acquire KalVista Pharmaceuticals in a deal valued at about $1.9 billion, expanding the Italian biopharmaceutical company's rare disease portfolio with a newly approved treatment for a rare hereditary swelling disorder. 

  • April 29, 2026

    Hogan Lovells Rehires Baker McKenzie Chair As Partner In DC

    Hogan Lovells has rehired an attorney who was most recently the chair of Baker McKenzie's U.S. healthcare and life sciences regulatory practice, who advises life sciences, food, consumer platform and technology companies.

  • April 28, 2026

    Allergan Seeks Sanctions Over Discovery In Botox Fight

    Botox manufacturer Allergan has asked a Tennessee federal judge to sanction Revance Therapeutics, claiming its attorneys made misrepresentations to run out the clock on discovery and prevent Allergan from obtaining essential information in a case alleging theft of trade secrets.

  • April 28, 2026

    5th Circ. Judge 'Hung Up' On FDA Vape Denial Reasoning

    A Fifth Circuit judge on Tuesday pressed the U.S. Food and Drug Administration on how it reviews applications from flavored vape manufacturers, asking why repeatedly denying applicants on similar grounds should not be treated as a rule requiring notice-and-comment.

  • April 28, 2026

    Teleflex Settles Catheter Patent Case Against Medtronic

    Medical device company Teleflex and Medtronic have reached a settlement to end a catheter patent dispute from which a judge recused himself after explaining he was "at a loss" on how to proceed.

  • April 28, 2026

    Ex-Fauci Adviser Charged With Concealing COVID Records

    Federal prosecutors have charged a former adviser to Dr. Anthony Fauci with deleting government emails and using his personal email account to dodge public records requests about the origins of the COVID-19 virus.

  • April 28, 2026

    Purdue Pharma's $5.5B Plea Deal Clinched As Survivors Protest

    OxyContin maker Purdue Pharma LP has to pay a $3.5 billion fine and forfeit an additional $2 billion, more than five years after it pled guilty to criminal charges related to its role in the opioid crisis, a New Jersey federal judge said Tuesday.

  • April 28, 2026

    MedMal Case Volume Declines, But Doctor Risks Remain High

    While the volume of malpractice lawsuits against U.S. physicians has dropped in recent years, that doesn't mean the threat of legal liability is dissipating, according to a report released Monday by the American Medical Association. 

  • April 28, 2026

    Paul Hastings, Gibson Dunn Steer $739M Ligand-Xoma Deal

    Ligand Pharmaceuticals said it plans to purchase XOMA Royalty in a $739 million deal combining the two biotechnology royalty aggregator companies advised by Gibson Dunn & Crutcher LLP and Paul Hastings LLP.

  • April 28, 2026

    Walgreens Can't Use Recording To Undo Investor Claim In Ill.

    An Illinois federal judge has said she won't toss a claim brought by shareholders alleging a former Walgreens president made a false and misleading statement during an investor conference, rejecting the company's argument that an audio recording of that conference warranted a second look at her dismissal ruling.

  • April 28, 2026

    Chinese Man Extradited From Italy Over COVID Data Theft

    A Chinese citizen has appeared before a Houston federal court after being extradited from Italy to face charges for his alleged role in the Microsoft "HAFNIUM" cyberattack that was allegedly orchestrated by the Chinese government to target U.S. COVID-19 research.

  • April 28, 2026

    Hikma, Cipla Cut Deals In Pfizer Heart Drug Patent Case

    Hikma Pharmaceuticals PLC and Cipla Ltd. have reached settlements with Pfizer Inc. in a case over the two defendants' efforts to create generic versions of the heart medication Vyndamax.

  • April 28, 2026

    Maryland Justices Allow IVF Cost Class Action To Proceed

    A Maryland couple can pursue a proposed class action against a health insurer that they say wrongfully denied coverage for embryo thawing in connection with an in vitro fertilization procedure, the Maryland Supreme Court has ruled, finding that the insurer's subsequent payment of the claim doesn't moot the suit.

  • April 28, 2026

    Eli Lilly Inks $2.25B AI Genetics Research Pact With Profluent

    AI-focused biotech Profluent said Tuesday it has entered a multiprogram, strategic research collaboration with Eli Lilly and Co. to treat diseases with high unmet need, in a deal that involves an upfront payment and up to $2.25 billion in additional milestone payments. 

  • April 28, 2026

    Meet The Attys Arguing The High Court 'Skinny Label' Case

    When the U.S. Supreme Court hears arguments Wednesday in a patent case involving "skinny labels" on generic drugs, a longtime patent attorney as well as a government attorney who often handles intellectual property cases will face an appellate specialist who has argued many high court cases.

  • April 27, 2026

    North Dakota Drug-Pricing Law Blocked In Pharma Fight

    A North Dakota federal judge on Monday blocked the state's new drug-pricing law, agreeing with pharmaceutical companies that while the law purports to "protect the underdogs," it illegally interferes with the federal drug-pricing regime.

  • April 27, 2026

    Did Hedge Fund 'Greed' Hurt Vaxart Investors? Jury To Decide

    Armistice Capital and two of its executives used misleading press releases to pump and dump $250 million in Vaxart stock during the pandemic through misleading press releases in an act of pandemic-era "greed," investors' counsel told a California federal jury during closing arguments Monday, while the hedge fund defendants' lawyer countered Vaxart's announcements were "true and accurate."

  • April 27, 2026

    DOJ Says Wash. 340B Drug Law Is Preempted In Novartis Suit

    The U.S. Department of Justice waded into a dispute between pharmaceutical giants and the state of Washington on Monday, arguing that federal law preempts a new state law that expands discounts that drugmakers must provide under the federal 340B Drug Pricing Program.

  • April 27, 2026

    High Court Appears Split In Monsanto Roundup Appeal

    Monsanto's efforts to stem the tide of thousands of lawsuits over its blockbuster weedkiller Roundup seemed to find a mixed audience with the U.S. Supreme Court justices Monday as they debated the benefits of national labeling standards with how regulators stay on top of changing science.

  • April 27, 2026

    Moderna Hit With Suit Over CureVac COVID Patents

    BioNTech subsidiary CureVac has launched a new patent infringement suit against Moderna, claiming its COVID-19 vaccine infringed a handful of patents, saying the Massachusetts-based company "exploited" its messenger RNA technology.

  • April 27, 2026

    Attys, Advocates Call DOJ Pot Rule Historic Shift For Feds

    Legal strategies are evolving quickly in the wake of last week's "historic" rescheduling of state-legal medical cannabis, as a group of attorneys and advocates gathered Monday to evaluate the trade-offs of dispensaries now being able to register like pharmacies with the feds and the potential effect on industry investments and trade.

  • April 27, 2026

    IQVIA Accuses Ex-Execs, Syneos Of Poaching $180M Client

    IQVIA Holdings Inc. is accusing former executives of defecting to a competitor in the clinical research organization industry and initiating a corporate raid that resulted in the loss of one customer worth at least $180 million, according to a lawsuit filed in North Carolina Business Court.

  • April 27, 2026

    4 Firms Build Astorg's $1.1B Microbiology Biz Buy

    Life sciences company Thermo Fisher Scientific Inc. on Monday announced plans to sell its microbiology business to European private equity firm Astorg in an over $1.1 billion deal steered by four law firms.

  • April 27, 2026

    3rd Circ. Panel Once Again Backs Talc Co. Whittaker's Ch. 11

    The Third Circuit on Monday upheld its decision that Whittaker Clark & Daniels was authorized to file for Chapter 11 and certain claims against the defunct talc supplier's corporate successor belong to the debtor, not personal injury claimants.

Expert Analysis

  • Opinion

    USPTO Should Let Inventors Valuate Patents In Prosecution

    Author Photo

    By building patent valuation into the application process, rather than waiting until potential litigation years down the line, the U.S. Patent and Trademark Office would streamline the process for inventors protecting and enforcing their patents, says John Powers at Powers IP.

  • 2 Discovery Rulings Break With Heppner On AI Privilege Issue

    Author Photo

    While a New York federal court’s recent ruling in U.S. v. Heppner suggests that some litigants’ communications with AI tools are discoverable, two other recent federal court decisions demonstrate that such interactions generally qualify for work-product protection under the Federal Rules of Civil Procedure, says Joshua Dunn at Brown Rudnick.

  • Series

    Isshin-Ryu Karate Makes Me A Better Lawyer

    Author Photo

    My involvement in martial arts, specifically Isshin-ryu, which has principles rooted in the eight codes of karate, has been one of the most foundational in the development of my personality, and particularly my approach to challenges — including in my practice of law, says Kaitlyn Stone at Barnes & Thornburg.

  • Microplastics On Water Contaminant List Could Spur Claims

    Author Photo

    The U.S. Environmental Protection Agency's proposal to include microplastics in its draft sixth Contaminant Candidate List under the Safe Drinking Water Act could influence consumer fraud claims and enforcement by state attorneys general, as well as claims against manufacturers from entities facing regulatory compliance costs, says Arie Feltman-Frank at Jenner & Block.

  • USPTO's AI Search Pilot May Reshape Patent Filing Strategy

    Author Photo

    The U.S. Patent and Trademark Office's new artificial intelligence search pilot aims to introduce earlier visibility into the prior art landscape, potentially influencing patent filing considerations and shifting the role of counsel to an earlier stage of the prosecution process, say attorneys at Foley & Lardner.

  • Peptide Policy Is Shifting Toward Sanctioned Compounding

    Author Photo

    The policy landscape for peptides is undergoing a significant shift under the Trump administration, moving toward a complex system of verified compounding and complementary enforcement that will likely bring peptides firmly back into the sphere of legitimate consumer products, say attorneys at Sheppard.

  • Keys To Building Defensible Psychedelic Therapy Programs

    Author Photo

    Given the rapidly evolving legal environment for psychedelic therapies and heightened liability and compliance risks facing providers, meticulous documentation, robust risk management protocols, and proactive engagement with professional organizations and insurers are essential strategies, say Kimberly Chew at Husch Blackwell and L. Alison McInnes at Mindful Health Solutions.

  • Opinion

    State Bars Need To Get Specific About AI Confidentiality

    Author Photo

    Lawyers need to put actual client information into artificial intelligence tools to get their full value, but they cannot confidently do so until state bars offer clear, formal authority on which plan tiers of the three most popular generative AI tools are safe to use when sharing specific client details, says attorney Nick Berk.

  • Series

    Alpine Skiing Makes Me A Better Lawyer

    Author Photo

    Skiing has shaped habits I rely on daily as an attorney — focus, resilience and the ability to remain steady when circumstances shift rapidly — and influences the way I approach legal strategy, client counseling and teamwork, says Isaku Begert at Marshall Gerstein.

  • FDA Guidance May Move Goalposts For Form 483 Responses

    Author Photo

    New draft guidance from the U.S. Food and Drug Administration provides formal insight on how drug manufacturers are expected to respond to Form 483s, raising some concerns about the agency's timelines and expectations, say attorneys at Cooley.

  • 2 Strands Of Patent Law In High Court's 'Skinny Label' Case

    Author Photo

    Amarin v. Hikma, which is set for oral argument in the U.S. Supreme Court this month, highlights the distinction between two different strands of intellectual property law — analogizing a patent to either a property deed or a home, says Jonas McDavit at Spencer West.

  • Why MDLs Slow Down — And How To Speed Them Up

    Author Photo

    Multidistrict litigation has become central to mass tort practice, but as MDLs grow in size and complexity, so do delays and costs — so tools like the new federal rule governing MDLs, targeted use of special masters and strategically deployed Lone Pine orders are more essential than ever, say attorneys at Ice Miller.

  • A Check-Up On HHS' Push To Implement AI Infrastructure

    Author Photo

    The U.S. Department of Health and Human Services has made some headway in its efforts to implement artificial intelligence across its agencies, but will have to overcome a number of near-term tests in order to be successful, says Theodore Thompson at Stinson.

  • What A Court Doc Audit Reveals About Erroneous Filings

    Author Photo

    My audit of 1,522 court documents from last month found that over 95% contained at least one verifiable error, with fewer than 1% showing clear indicators of artificial intelligence use — highlighting above all else that lawyers may want to focus most on strengthening their review processes, says Elliott Ash at ETH Zurich.

  • Series

    Mich. Banking Brief: All The Notable Legal Updates In Q1

    Author Photo

    Michigan's financial services sector saw several significant developments in 2026's first quarter, including the state Department of Insurance and Financial Services' issuance of a bulletin on the use of artificial intelligence and the Michigan House's introduction of a bill based on the Model Money Transmission Modernization Act, say attorneys at Dykema.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.